Cyclacel Pharmaceuticals logo
Cyclacel Pharmaceuticals to Present at the 19th Annual Rodman & Renshaw Global Investment Conference
September 08, 2017 07:00 ET | Cyclacel
BERKELEY HEIGHTS, N.J., Sept. 08, 2017 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the Company), a clinical-stage biopharmaceutical company using...
Cyclacel Pharmaceuticals logo
Cyclacel Pharmaceuticals Reports Second Quarter 2017 Financial Results 
August 09, 2017 16:05 ET | Cyclacel
BERKELEY HEIGHTS, N.J., Aug. 09, 2017 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) ("Cyclacel" or the "Company"), a clinical-stage biopharmaceutical company using...
Cyclacel Pharmaceuticals logo
Cyclacel Announces Selection of Recommended Phase 2 Dose for CYC065 and Evidence of Durable Target Engagement and Mcl-1 Biomarker Suppression
August 07, 2017 07:00 ET | Cyclacel
BERKELEY HEIGHTS, N.J., Aug. 07, 2017 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the Company), a clinical-stage biopharmaceutical company using cell...
Cyclacel Pharmaceuticals logo
Cyclacel Announces Closing of $15.2 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option
July 21, 2017 14:00 ET | Cyclacel
BERKELEY HEIGHTS, N.J., July 21, 2017 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (Cyclacel or the Company), a clinical-stage biopharmaceutical company using cell cycle,...
Cyclacel Pharmaceuticals logo
Cyclacel Announces Pricing of $13.2 Million Underwritten Public Offering
July 19, 2017 08:30 ET | Cyclacel
BERKELEY HEIGHTS, N.J., July 19, 2017 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (Cyclacel or the Company), a clinical-stage biopharmaceutical company using cell cycle,...
Cyclacel Pharmaceuticals logo
Cyclacel Pharmaceuticals Reports First Quarter 2017 Financial Results
May 11, 2017 16:05 ET | Cyclacel
BERKELEY HEIGHTS, N.J., May 11, 2017 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) ("Cyclacel" or the "Company") a biopharmaceutical company developing oral...
Cyclacel Pharmaceuticals logo
Cyclacel Pharmaceuticals to Release First Quarter 2017 Financial Results
May 05, 2017 07:00 ET | Cyclacel
BERKELEY HEIGHTS, N.J., May 05, 2017 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral...
Cyclacel Pharmaceuticals logo
Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results
March 28, 2017 16:05 ET | Cyclacel
BERKELEY HEIGHTS, N.J., March 28, 2017 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) ("Cyclacel" or the "Company") a biopharmaceutical company developing oral...
Cyclacel Pharmaceuticals logo
Cyclacel’s CDK Inhibitor CYC065 Causes Anaphase Catastrophe, a Novel Cancer-Specific Mechanism of Action, in Research Published in JNCI
March 07, 2017 07:00 ET | Cyclacel
BERKELEY HEIGHTS, N.J., March 07, 2017 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"), today announced the publication of a...
Cyclacel Pharmaceuticals logo
Cyclacel’s CYC065 Demonstrates Promising Activity in MYCN-Addicted Neuroblastoma in Preclinical Data Presented at Childhood Cancer 2016
September 06, 2016 07:00 ET | Cyclacel
BERKELEY HEIGHTS, N.J., Sept. 06, 2016 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral...